Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse

Michael A Rogawski, Philip S. Kurzman, Shun Ichi Yamaguchi, He Li

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The role of AMPA and GluR5-containing kainate receptors in the development and expression of amygdala kindling was examined using the selective 2,3-benzodiazepine AMPA receptor antagonist GYKI 52466 [(1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiaze pine] and the decahydroisoquinoline mixed AMPA receptor and GluR5 kainate receptor antagonist LY293558 {(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoqu inoline-3-carboxylic acid)}. Administration of GYKI 52466 (5-40 mg/kg, intraperitoneally) and LY293558 (10-40 mg/kg, intraperitoneally) prior to daily kindling stimulation in mice produced a dose-dependent suppression of the rate of development of behavioral kindled seizure activity and reduced the duration of the stimulation-induced electrographic afterdischarge. In drug-free stimulation sessions after the initial drug-treatment sessions, there was an acceleration in the rate of kindling development compared with the rate during the preceding drug-administration period; the 'rebound' rate was also greater than the kindling rate in saline-treated control animals. In fully kindled animals, both GYKI 52466 and LY293558 produced a dose-dependent suppression of evoked seizures (ED50, 19.3 and 16.7 mg/kg, respectively). Although AMPA receptors appear to be critical to the expression of kindled seizures, since kindling development progressed despite the suppression of behavioral seizure activity, AMPA receptors are less important to the kindling process. LY293558 was modestly less effective at suppressing behavioral seizures during kindling and was not superior to GYKI 52466 in retarding the overall extent of kindling development, indicating that GluR5 kainate receptors do not contribute to epileptogenesis in this model.

Original languageEnglish (US)
Pages (from-to)28-35
Number of pages8
JournalNeuropharmacology
Volume40
Issue number1
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

tezampanel
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Amygdala
AMPA Receptors
Seizures
Pharmaceutical Preparations
GABA-A Receptors
Carboxylic Acids
Gluk1 kainate receptor
GYKI 52466

Keywords

  • AMPA receptor
  • Amygdala
  • Kainate receptor
  • Kindling
  • Seizure

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Drug Discovery
  • Pharmacology

Cite this

Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. / Rogawski, Michael A; Kurzman, Philip S.; Yamaguchi, Shun Ichi; Li, He.

In: Neuropharmacology, Vol. 40, No. 1, 2000, p. 28-35.

Research output: Contribution to journalArticle

Rogawski, Michael A ; Kurzman, Philip S. ; Yamaguchi, Shun Ichi ; Li, He. / Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. In: Neuropharmacology. 2000 ; Vol. 40, No. 1. pp. 28-35.
@article{cea3be9a52384301983475d848da046c,
title = "Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse",
abstract = "The role of AMPA and GluR5-containing kainate receptors in the development and expression of amygdala kindling was examined using the selective 2,3-benzodiazepine AMPA receptor antagonist GYKI 52466 [(1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiaze pine] and the decahydroisoquinoline mixed AMPA receptor and GluR5 kainate receptor antagonist LY293558 {(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoqu inoline-3-carboxylic acid)}. Administration of GYKI 52466 (5-40 mg/kg, intraperitoneally) and LY293558 (10-40 mg/kg, intraperitoneally) prior to daily kindling stimulation in mice produced a dose-dependent suppression of the rate of development of behavioral kindled seizure activity and reduced the duration of the stimulation-induced electrographic afterdischarge. In drug-free stimulation sessions after the initial drug-treatment sessions, there was an acceleration in the rate of kindling development compared with the rate during the preceding drug-administration period; the 'rebound' rate was also greater than the kindling rate in saline-treated control animals. In fully kindled animals, both GYKI 52466 and LY293558 produced a dose-dependent suppression of evoked seizures (ED50, 19.3 and 16.7 mg/kg, respectively). Although AMPA receptors appear to be critical to the expression of kindled seizures, since kindling development progressed despite the suppression of behavioral seizure activity, AMPA receptors are less important to the kindling process. LY293558 was modestly less effective at suppressing behavioral seizures during kindling and was not superior to GYKI 52466 in retarding the overall extent of kindling development, indicating that GluR5 kainate receptors do not contribute to epileptogenesis in this model.",
keywords = "AMPA receptor, Amygdala, Kainate receptor, Kindling, Seizure",
author = "Rogawski, {Michael A} and Kurzman, {Philip S.} and Yamaguchi, {Shun Ichi} and He Li",
year = "2000",
doi = "10.1016/S0028-3908(00)00112-X",
language = "English (US)",
volume = "40",
pages = "28--35",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse

AU - Rogawski, Michael A

AU - Kurzman, Philip S.

AU - Yamaguchi, Shun Ichi

AU - Li, He

PY - 2000

Y1 - 2000

N2 - The role of AMPA and GluR5-containing kainate receptors in the development and expression of amygdala kindling was examined using the selective 2,3-benzodiazepine AMPA receptor antagonist GYKI 52466 [(1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiaze pine] and the decahydroisoquinoline mixed AMPA receptor and GluR5 kainate receptor antagonist LY293558 {(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoqu inoline-3-carboxylic acid)}. Administration of GYKI 52466 (5-40 mg/kg, intraperitoneally) and LY293558 (10-40 mg/kg, intraperitoneally) prior to daily kindling stimulation in mice produced a dose-dependent suppression of the rate of development of behavioral kindled seizure activity and reduced the duration of the stimulation-induced electrographic afterdischarge. In drug-free stimulation sessions after the initial drug-treatment sessions, there was an acceleration in the rate of kindling development compared with the rate during the preceding drug-administration period; the 'rebound' rate was also greater than the kindling rate in saline-treated control animals. In fully kindled animals, both GYKI 52466 and LY293558 produced a dose-dependent suppression of evoked seizures (ED50, 19.3 and 16.7 mg/kg, respectively). Although AMPA receptors appear to be critical to the expression of kindled seizures, since kindling development progressed despite the suppression of behavioral seizure activity, AMPA receptors are less important to the kindling process. LY293558 was modestly less effective at suppressing behavioral seizures during kindling and was not superior to GYKI 52466 in retarding the overall extent of kindling development, indicating that GluR5 kainate receptors do not contribute to epileptogenesis in this model.

AB - The role of AMPA and GluR5-containing kainate receptors in the development and expression of amygdala kindling was examined using the selective 2,3-benzodiazepine AMPA receptor antagonist GYKI 52466 [(1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiaze pine] and the decahydroisoquinoline mixed AMPA receptor and GluR5 kainate receptor antagonist LY293558 {(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoqu inoline-3-carboxylic acid)}. Administration of GYKI 52466 (5-40 mg/kg, intraperitoneally) and LY293558 (10-40 mg/kg, intraperitoneally) prior to daily kindling stimulation in mice produced a dose-dependent suppression of the rate of development of behavioral kindled seizure activity and reduced the duration of the stimulation-induced electrographic afterdischarge. In drug-free stimulation sessions after the initial drug-treatment sessions, there was an acceleration in the rate of kindling development compared with the rate during the preceding drug-administration period; the 'rebound' rate was also greater than the kindling rate in saline-treated control animals. In fully kindled animals, both GYKI 52466 and LY293558 produced a dose-dependent suppression of evoked seizures (ED50, 19.3 and 16.7 mg/kg, respectively). Although AMPA receptors appear to be critical to the expression of kindled seizures, since kindling development progressed despite the suppression of behavioral seizure activity, AMPA receptors are less important to the kindling process. LY293558 was modestly less effective at suppressing behavioral seizures during kindling and was not superior to GYKI 52466 in retarding the overall extent of kindling development, indicating that GluR5 kainate receptors do not contribute to epileptogenesis in this model.

KW - AMPA receptor

KW - Amygdala

KW - Kainate receptor

KW - Kindling

KW - Seizure

UR - http://www.scopus.com/inward/record.url?scp=0035219751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035219751&partnerID=8YFLogxK

U2 - 10.1016/S0028-3908(00)00112-X

DO - 10.1016/S0028-3908(00)00112-X

M3 - Article

VL - 40

SP - 28

EP - 35

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 1

ER -